CommentaryExtended-spectrum β-lactamases: A challenge for clinical microbiologists and infection control specialists
Section snippets
Background
Since the early 1980s, third-generation cephalosporins have become an important tool in the treatment of severe infections. Unfortunately, clavulanic acid-inhibited extended-spectrum β-lactamases (ESBLs), a heterogeneous group of plasmid- and integron-encoded enzymes responsible for resistance against almost all penicillins, cephalosporins (except cephamycins), and other monobactams,1 have been developed by a great number of bacterial species. Because the above-mentioned drugs were often found
Bacterial species and ESBL types
As mentioned above, TEM and SHV enzyme types are the most common ESBLs mostly found in Klebsiella pneumoniae and Escherichia coli. A total of more than one hundred different enzymes are included in both families together. Recently, these and other types of ESBLs have also been detected in Klebsiella oxytoca, Proteus mirabilis, nontyphoid Salmonella species, other members of the Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter spp.11, 12
In general, there is a considerable geographic
Prevalence of ESBLs
According to a survey by the National Committee for Clinical Laboratory Standards (NCCLS), the prevalence of ESBLs is probably underestimated.23 Estimates of ESBL-producing isolates among Enterobacteriaceae range from a national average of 3% in the United States21 to much higher numbers in Europe, where the prevalence of ESBL production among isolates of Enterobacteriaceae varies greatly from country to country. In The Netherlands, a survey of 11 hospital laboratories showed that <1% of E coli
Risk factors for acquirement
Several case-control studies have evaluated the risk factors for colonization or infection with ESBL-producing organisms in the hospitalized patient. Reported risk factors include presence of intravascular catheters, emergency intraabdominal surgery, gastrostomy or jejunostomy tube, gastrointestinal colonization, length of hospital or intensive care unit stay, prior antibiotics (including third-generation cephalosporins), prior nursing home stay, severity of illness, presence of a urinary
Clinical significance
Although it is widely accepted that in vitro susceptibility of ESBL-producing organisms to broad-spectrum cephalosporins does not necessarily predict success of treatment, this fact was barely demonstrated in well-designed trials. However, numerous case reports and field experience could lead to such a conclusion: Mortality rates varying from 42% to 100% have been reported when patients infected by ESBL-producing organisms were treated with cephalosporins. A multicountry study conducted by
Detection and reporting
Detection of organisms producing these enzymes can be difficult because the presence of ESBLs in a bacterial cell does not always produce a resistance phenotype when one is using the traditional minimal inhibitory concentration (MIC) and disk diffusion interpretative criteria published by the National Committee for Clinical Laboratory Standards (NCCLS). The fact that ESBL strains cannot be detected by the routine antimicrobial susceptibility testing (AST) used in most laboratories facilitate
Antibiotic therapy
ESBL-producing bacteria often show cross-resistance with other groups of antibiotics, such as fluoroquinolones. In 2 different studies, 18% of ESBL-producing isolates were also ciprofloxacin resistant.39, 40 The close relationship between ESBL production and quinolone resistance is particularly worrisome because the first reported instance of plasmid-mediated ciprofloxacin resistance has been in an isolate of K pneumoniae also possessing an ESBL. However, this phenomenon is still very rare.41
Conclusions
Bacterial resistance to antimicrobial treatment is emerging as one of the major public health threats at the beginning of the 21st Century. The widespread use and, in some cases, misuse of antimicrobials in all health care settings over the past several decades has been cited as a contributing factor in the development of drug resistance in virtually all bacterial species.
The emergence of resistance in bacterial strains that had been consistently susceptible to standard antimicrobial therapy is
References (44)
Clinical strategies for serious infection: a North American perspective
Diagn Microbiol Infect Dis
(1998)- et al.
CTX-M-type beta-lactamases: an emerging group of extended-spectrum enzymes
Int J Antimicrob Agents
(2000) Evolution and epidemiology of extended-spectrum β-lactamases (ESBLs) and ESBL-producing microorganisms
Clin Microbiol Infect
(2001)- et al.
Prevalence of extended spectrum β-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99)
Diagn Microbiol Infect Dis
(2002) - et al.
Antimicrobial susceptibility of community-acquired uropathogens in Northern Israel
Int J Antimicrob Agents
(2001) Is it important to identify extended spectrum β-lactamase producing isolates?
Eur J Clin Microb Infect Dis
(1996)β-Lactamases in laboratory and clinical resistance
Clin Microbiol Rev
(1995)- et al.
Escherichia coli and Klebsiella pneumoniae strains more susceptible to cefoxitin than to third generation cephalosporins
J Antimicrob Chemother
(1983) - et al.
Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility pattern
Rev Infect Dis
(1988) - et al.
Broad-spectrum, transmissible β-lactamases
N Engl J Med
(1988)
Novel plasmid-mediated β-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae
Antimicrob Agents Chemother
Dissemination of cephalosporin-resistant Serratia marcescens strains producing a plasmidic SHV type β-lactamase in Greek hospitals
Eur J Clin Microbiol Infect Dis
Prevalence of extended-spectrum β-lactamase-producing Enterobacter cloacae in the Asia-Pacific region: results from the SENTRY Antimicrobial Surveillance Program, 1998 to 2001
Antimicrob Agents Chemother
OXA-11, an extended-spectrum variant of OXA-10 (PSE-2) β-lactamase from Pseudomonas aeruginosa
Antimicrob Agents Chemother
Spread of a Salmonella typhimurium clone resistant to expanded-spectrum cephalosporins in three European countries
J Clin Microbiol
Dissemination of CTX-M-3 and CMY-2 β-lactamases among clinical isolates of Escherichia coli in southern Taiwan
J Clin Microbiol
OXA-11, an extended-spectrum variant of OXA-10 (PSE-2) β-lactamase from Pseudomonas aeruginosa
Antimicrob Agents Chemother
OXA-28, an extended-spectrum variant of OXA-10 β-lactamase from Pseudomonas aeruginosa and its plasmid- and integron-located gene
Antimicrob Agents Chemother
Widespread detection of PER-1-type extended-spectrum β-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study
Antimicrob Agents Chemother
Outbreak of extended-spectrum β-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a French hospital
J Clin Microbiol
Plasmid-mediated, carbapenem-hydrolysing β-lactamase, KPC-2, in Klebsiella pneumoniae isolates
J Antimicrob Chemother
Cited by (50)
Carbapenem susceptibility among Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae isolates obtained from patients in intensive care units in Taiwan in 2005, 2007, and 2009
2015, Diagnostic Microbiology and Infectious DiseaseCitation Excerpt :Since the last decade, the rates of antibiotic resistance among Gram-negative bacilli (GNB) were on the unstoppable escalation (Colodner, 2005; Talbot, 2010; Woodford et al., 2004).
Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: Results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007
2015, Journal of Microbiology, Immunology and InfectionCitation Excerpt :During the past three decades, Gram-negative bacilli (GNBs) have gradually become resistant to a number of antibiotics.1,2
Cephalosporin and fluoroquinolone combinations are highly associated with CTX-M β-lactamase-producing Escherichia coli: A case-control study in a French teaching hospital
2011, Clinical Microbiology and InfectionCitation Excerpt :Nevertheless, most of the tested strains were CTX-M15 (personal data) as previously described in France [12]. Concerning antimicrobial susceptibilities, our data confirm that carbapenems remain active against CTX-M-producing E. coli and are considered to be the treatment of choice against serious ESBL-associated infections [2,12–16]. As for β-lactam inhibitors—not surprisingly, tazobactam is less inactivated by CTX-M type enzymes than clavulanic acid [17].
Hospital-Acquired Pneumonia: Pathophysiology, Diagnosis, and Treatment
2009, Surgical Clinics of North AmericaCitation Excerpt :ESBL-producing strains are considered resistant to all beta-lactam agents.20 They additionally demonstrate a high rate of concomitant resistance to fluoroquinolones, making carbapenems the recommended first-line agents for ESBL-producing strains.19,20 P aeruginosa is the most common multidrug-resistant gram-negative bacillus causing HAP/VAP1,16 and is the most frequent VAP isolate in patients on mechanical ventilation for more than 4 days.7
Prevalence of AmpC, ESBL, and colistin resistance genes in Enterobacterales isolated from ready-to-eat food in Algeria
2023, Brazilian Journal of Microbiology